St Andrews-based investment firm Eos Advisory has appointed Chris Brinsmead CBE as a partner.
He is a council member at Imperial College London, a former adviser to the UK Government on life sciences, and has previously held senior executive roles at ICI and AstraZeneca,
Over the last decade, Brinsmead has also been a non-executive board member and chair on a number of private and public limited company boards.
Eos Advisory managing partner Andrew McNeill said: “We have always had an enormous amount of respect for Chris’s achievements in the UK and international pharmaceutical sector, and have then had the pleasure of working more closely with Chris on Cumulus Oncology and other Eos-backed ventures in recent times.
“Bringing Chris on board is a milestone event for the firm and is a sign of our ambitions for the future.”
Brinsmead commented: “I am excited to identify and work with startup companies, conceived in Scotland, focussed on four distinct themes, all of which can have an impact worldwide.”
Founded by chairman Kevin Grainger in 2014, Eos has a portfolio of 13 investee companies – including ILC Therapeutics, 3FBio, Xelect and Cumulus Oncology – investing in four key impact areas: disease prevention and treatment; energy security, climate change and pollution; food and water security; sustainability of industrial processes and infrastructure.
In November, Eos appointed Mark Beaumont to its leadership team to help deliver its strategic growth plans over the coming years.
The strengthening of the senior executive team is the first in a series of forthcoming announcements which support the firm’s future strategy.
Earlier this month, Eos led the investment round into RAB-Microfluidics, the Aberdeen-headquartered “laboratory on a chip” oil analysis startup.